RD&C together with ICIQ develops novel co-crystals and crystalline multi-component structures formed by two or more molecules to generate synergistic efficacy based on improved bioavailability, increased solubility, or decreased plasma protein binding of current treatment options pursuing the concept of polypharmacology, the treatment of diseases by modulating more than one target.